Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

354

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

June 30, 2025

Conditions
Tuberculosis, PulmonaryTuberculosis, MDRTuberculosis Infection
Interventions
DRUG

Control group

placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks

DRUG

ASA group

Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)

DRUG

IBU group

Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)

DRUG

SoC TB

Standard of Care Tuberculosis treatment

Trial Locations (3)

1864

RECRUITING

Perinatal HIV Unit (PHRU)- Chris Hani Baragwanath Hospital, Soweto

Unknown

RECRUITING

National Center for Tuberculosis and Lung Diseases, Tbilisi

RECRUITING

PHRU- Matlosana, Tshepong Hospital MDR Unit, Klerksdorp

All Listed Sponsors
collaborator

National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia

OTHER

collaborator

Perinatal HIV Research Unit of the University of the Witswatersrand

OTHER

lead

Fundació Institut Germans Trias i Pujol

OTHER

NCT04575519 - Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis | Biotech Hunter | Biotech Hunter